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Abstract
Hemangiomas are tumors formed by hyper-proliferation of vascular endothelial cells. This is caused by elevated vascular
endothelial growth factor (VEGF) signaling through VEGF receptor 2 (VEGFR2). Here we show that elevated VEGF levels
produced by hemangioma endothelial cells are reduced by the mTOR inhibitor rapamycin. mTOR activates p70S6K, which
controls translation of mRNA to generate proteins such as hypoxia inducible factor-1 (HIF-1). VEGF is a known HIF-1 target
gene, and our data show that VEGF levels in hemangioma endothelial cells are reduced by HIF-1a siRNA. Over-expression of
HIF-1a increases VEGF levels and endothelial cell proliferation. Furthermore, both rapamycin and HIF-1a siRNA reduce
proliferation of hemangioma endothelial cells. These data suggest that mTOR and HIF-1 contribute to hemangioma
endothelial cell proliferation by stimulating an autocrine loop of VEGF signaling. Furthermore, mTOR and HIF-1 may be
therapeutic targets for the treatment of hemangiomas.
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Introduction
Hemangiomas are the most common tumors found in children.
These vascular anomalies arise via uncontrolled angiogenesis
through clonal expansion of vascular endothelial cells [1].
Heterozygous single amino acid substitutions in VEGFR2 or
TEM8 have been found in hemangioma patients and have been
linked to reduced NFATc2-dependent expression of VEGFR1 [2].
As a decoy receptor that binds and sequesters VEGF and prevents
it from activating VEGFR2 [3], the low level of VEGFR1
expression by hemangioma endothelial cells causes constitutive
VEGF signaling through VEGFR2. This results in increased
proliferation of the cells and tumor formation [2].
HIF-1 is a transcription factor that is activated during hypoxia
by a mechanism that involves stabilization of HIF-1 protein levels
[4–6]. However, various signaling pathways can also increase
expression and activity of HIF-1 [7]. The kinase p70S6K controls
translation of mRNA to protein for factors such as HIF-1 [8,9].
Therefore, phosphorylation of p70S6K through a constitutive
signaling pathway such as the VEGFR2 pathway in hemangioma
endothelial cells might increase HIF-1 activity. p70S6K has been
shown to be phosphorylated by mTOR [10], a downstream
signaling molecule in the phosphoinositide-3 kinase (PI3K)
pathway [11,12]. We previously showed that PI3K is constitutively
active as a result of enhanced VEGF-dependent VEGFR2
signaling in hemangioma endothelial cells [2]. Rapamycin, a
known mTOR inhibitor [13,14], can be used to determine the role
of this pathway in regulating biochemical and physiological
processes. Also, VEGF is a known HIF-1 target gene [15,16].
Based on these findings, we sought to determine whether a HIF-
1-dependent autocrine loop of VEGF signaling might contribute
to the hyper-proliferation of hemangioma endothelial cells. We
also asked whether rapamycin could inhibit HIF-1 expression and
reduce VEGF signaling in these cells.
Results
To determine HIF-1a protein levels we performed immuno-
blotting using lysates from cultured normal human dermal
microvascular endothelial cells (HDMEC) and hemangioma
endothelial cells (EC2, EC17B, EC21A). We found that heman-
gioma endothelial cells show significantly higher expression of
HIF-1a than in control cells (Figure 1A and S1). Immunocyto-
chemistry showed constitutive nuclear localization of activated
HIF-1a in hemangioma endothelial cells, but not in control
endothelial cells (Figure 1B).
To determine whether the elevated levels of HIF-1a found in
hemangioma endothelial cells is the result of their constitutive
VEGF/VEGFR2 signaling as previously described [2], we treated
cells for 6 hours with neutralizing antibodies specific for VEGF-
A165. Luminex assays were performed to measure real-time
quantitative protein expression levels of HIF-1a. The data showed
that the VEGF antibodies significantly reduced the elevated HIF-
1a levels in hemangioma endothelial cells (Figure 1C). We
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constitutive PI3K/AKT signaling as a result of this VEGF activity
[2]. Addition of a chemical inhibitor of PI3K (LY294002) was
sufficient to reduce elevated HIF-1a levels in hemangioma
endothelial cells almost to the levels of control endothelial cells
(Figure 1D).
To assess the effects of HIF-1a siRNA in the primary control and
hemangioma endothelial cells, we performed immunoblotting and
Luminex assays using lysates from cells transfected with either HIF-
1a siRNA or a negative control siRNA duplex. Our data show a
substantial knockdown of HIF-1a protein expression by HIF-1a
siRNA(Figure2Aand2B).ToestablishwhethertheelevatedVEGF
levels observed in hemangioma endothelial cells are the result of
HIF-1a activity, we performed immunoblotting and Luminex
analysis using the same siRNA treated samples. HIF-1a siRNA
significantly reduced the higher levels of VEGF-A165 in hemangi-
oma endothelial cells (Figure 2A and 2C). These data were
confirmed with a second HIF-1a siRNA duplex (Figure S2A and
S2B).
Next, we sought to confirm a role for HIF-1a on the
proliferation rates of hemangioma endothelial cells. Cultured
normal or hemangioma endothelial cells transfected with HIF-1a
siRNA or negative control siRNA were stained in suspension for
BrdU incorporation. Hemangioma endothelial cells showed much
higher proliferation rates than control cells. HIF-1a siRNA
significantly reduced the hyper-proliferation of hemangioma
endothelial cells (Figure 3A and 3B). These results were confirmed
by quantifying the total number of cells in culture over time
(Figure S3A) and by using a second HIF-1a siRNA duplex (Figure
S2C).
To determine whether HIF-1 expression increases VEGF levels
we decided to over-express HIF-1a in control endothelial cells
(HDMEC) using a pcDNA3-HIF-1a plasmid. Cells transfected
with the HIF-1a expression plasmid showed higher levels of HIF-
1a and VEGF-A165 protein by immunoblotting compared to those
transfected with the pcDNA3 empty vector (Figure 4A). Flow
cytometry was performed to assess cell proliferation by BrdU
staining. Cells containing the HIF-1a expression plasmid showed
higher BrdU incorporation compared to those with the empty
vector. However, in the presence of VEGF-A165 neutralizing
antibodies, the HIF-1a-dependent increase in cell proliferation
was blocked (Figure 4B and 4C). These results were confirmed by
quantifying the total cell numbers in culture over time (Figure
S3B).
To confirm that VEGF signaling can induce synthesis of HIF-
1a, we treated control endothelial cells with recombinant VEGF-
Figure 1. Elevated HIF-1 expression in hemangioma endothelial cells caused by VEGF/PI3K signaling. A: Immunoblotting showing high
expression of HIF-1a in hemangioma endothelial cells (EC2, EC17B, EC21A) compared to normal endothelial cells (HDMEC). B: Immunocytochemistry
showing constitutive nuclear localization of HIF-1a in hemangioma endothelial cells. C and D: Luminex analyses demonstrating that elevated HIF-1a
levels in hemangioma endothelial cells are reduced in the presence of VEGF-A165 neutralizing antibodies (VEGF Ab) or a chemical inhibitor of PI3K
(LY294002). Data represent mean (n=3)6SD; *P,0.01 compared to IgG or vehicle.
doi:10.1371/journal.pone.0042913.g001
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p70S6K after 15 minutes of treatment, a kinase known to promote
translation of HIF-1 mRNA into protein [8,9]. The mTOR
inhibitor rapamycin successfully inhibited VEGF-dependent
increases in p70S6K phosphorylation (Figure 5A). Increased
HIF-1a expression was observed in cells treated with VEGF for
6 hours, and total VEGF-A165 levels themselves were also higher
when stimulating cells with exogenous VEGF-A165, suggesting an
autocrine loop of VEGF signaling. Exposing the cells to rapamycin
inhibited VEGF-dependent expression of HIF-1a and VEGF
(Figure 5B). Exposing the cells to HIF-1a siRNA inhibited VEGF-
dependent increases in cell proliferation as determined by flow
cytometry analysis of BrdU staining (Figure 5C and 5D) or by
counting cells is culture over time (Figure S3C).
We next attempted to assess potential therapeutic effects of
rapamycin on hemangioma endothelial cells, since their elevated
proliferation is caused by hyperactive VEGF signaling [2].
Immunoblotting and Luminex analysis showed that hemangioma
endothelial cells have constitutively higher phosphorylation of
p70S6K and higher expression of HIF-1a and VEGF-A165
compared to control cells. Treatment of these cells with rapamycin
for 6 hours dramatically decreased p70S6K phosphorylation,
HIF-1a expression, and VEGF-A165 expression (Figure 6A–6C).
To measure proliferation rates of control and hemangioma
endothelial cells, we performed BrdU staining of cells treated in
culture with vehicle or rapamycin. Hemangioma endothelial cells
showed a much higher rate of proliferation than normal
endothelial cells. This hyper-proliferation of hemangioma endo-
thelial cells was significantly reduced by exposure to rapamycin
(Figure 7A and 7B). These data were confirmed by quantifying
total cell numbers in culture over time (Figure S3D).
Taken together, our data suggest that constitutive VEGF-
dependent mTOR signaling in hemangioma endothelial cells
promotes HIF-1 activity, which increases expression of VEGF to
form an autocrine loop of signaling (Figure 8). This mechanism
enhances proliferation of hemangioma endothelial cells.
Discussion
Our results provide novel insight into the mechanism that
control hyper-proliferation of hemangioma endothelial cells. Our
previous studies identified VEGF, VEGFR1, and VEGFR2 as
potential targets for therapeutic treatment of hemangiomas.
Treating hemangioma endothelial cells with VEGF neutralizing
antibodies, recombinant soluble VEGFR1, or VEGFR2 siRNA
was sufficient to reduce their proliferation [2]. Here we show that
the PI3K–mTOR–p70S6K signaling pathway is constitutively
active in hemangioma endothelial cells. As a result of this activity,
the expression of a downstream target, HIF-1a, is up-regulated.
HIF-1 has been shown to be constitutively located in the nuclei of
hemangioma endothelial cells in vivo [17]. However, it has been
unclear as to what potential role HIF-1 plays in promoting the
hemangioma phenotype. We demonstrate that HIF-1 is a major
contributor to the elevated VEGF levels produced in hemangioma
endothelial cells, and that decreased expression of HIF-1 reduces
proliferation of these cells.
Based on our data, it is clear that other factors besides HIF-1 are
involved in hemangioma endothelial cell proliferation. VEGF
signals through many pathways besides mTOR, which may play a
significant role in controlling proliferation. This would explain
why reduced proliferation rates after knockdown of HIF-1 with
siRNA were significant, but not dramatic. Furthermore, rapamy-
cin may have other effects on inhibiting proliferation other than
regulating HIF-1-dependent VEGF expression. Rapamycin had a
much greater effect on hemangioma endothelial cell proliferation
than by direct knockdown of HIF-1 with siRNA. Interestingly,
rapamycin also had a significant effect on the proliferation of
control endothelial cells, whereas HIF-1 siRNA did not.
Rapamycin is a potent inhibitor of the mTOR pathway and
treatment of hemangioma cells with rapamycin results in a
significant decrease in HIF-1 and VEGF levels and reduced
proliferation. Treatment with rapamycin may therefore prove
effective in the clinical management of large and rapidly
proliferating hemangiomas. Given the serious adverse effects of
rapamycin-based drugs when administered systemically to adult
and pediatric patients [18,19], systemic treatments with rapamycin
for even large hemangiomas is not advisable. However, recent
efforts to develop and clinically test topical rapamycin-based
therapy for cutaneous facial angiofibromas [20], the benign
tumors seen in patients with tuberous sclerosis [21], may provide a
basis for considering topical cutaneous rapamycin treatment also
for infantile hemangiomas. The outcome of randomized double
blind Phase I clinical trials for patients with tuberous sclerosis [20]
will provide a useful guide for further efforts along this line.
Figure 2. Elevated VEGF levels in hemangioma endothelial
cells are HIF-1-dependent. A: Immunoblotting showing the
expression knockdown effects of HIF-1a siRNA on HIF-1a and VEGF-
A165 in normal (HDMEC) and hemangioma (EC2, EC17B, EC21A)
endothelial cells. B and C: Luminex analysis showing suppression of
HIF-1a and VEGF-A165 protein levels in hemangioma endothelial cells by
HIF-1a siRNA. Data represent mean (n=3)6SD; *P,0.05 compared to
control siRNA.
doi:10.1371/journal.pone.0042913.g002
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Ethics Statement
All cells were obtained from patients with informed written
consent and protocols for this study approved by the Investiga-
tional Review Board of Harvard Medical School (IRB# M10510-
110). The investigation conformed to the principles outlined in the
Declaration of Helsinki.
Cell Culture
Primary human dermal microvascular endothelial cells derived
from foreskin (HDMEC) or facial skin (HCMEC), human
umbilical vein endothelial cells (HUVEC), and primary human
hemangioma endothelial cells (EC2, EC17B, EC21A) derived
from three different proliferating-phase hemangioma tumors were
isolated as previously described [1]. Cells were tested for purity
and found to express no markers for lymphatic endothelial cells or
stromal cells (pericytes, smooth muscle cells, fibroblasts, etc.) as
previously described [2,22]. Cells were grown in standard culture
conditions of 5% CO2 at 37uC using EGM-2 medium (Cambrex),
containing 20% FBS and 1% Penicillin/Streptomycin, followed by
human endothelial serum free medium (Gibco) 24 hours prior to
all experimental conditions. Rapamycin (Sigma-Aldrich) was used
at a concentration of 10 nM. Recombinant VEGF-A165 (R&D
Systems) was added at a concentration of 25 ng/ml. The PI3K
inhibitor LY294002 (Cell Signaling Technology) was used at a
concentration of 50 mM and added to the cultures 1 hour prior to
experimental conditions. VEGF-A165 neutralizing antibodies
Figure 3. Inhibiting HIF-1 expression decreases proliferation of hemangioma endothelial cells. A: Flow cytometry analysis of BrdU
incorporation in normal (HDMEC) and hemangioma (EC2, EC17B, EC21A) endothelial cells transfected with control or HIF-1a siRNA duplexes. B:
Quantification of BrdU incorporation showing decreased proliferation of hemangioma endothelial cells transfected with HIF-1a siRNA. Data represent
mean (n=3)6SD; *P,0.05 compared to control siRNA.
doi:10.1371/journal.pone.0042913.g003
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pcDNA3-HIF-1a expression plasmid was provided by Dr.
Ernestina Schipani (Indiana University School of Medicine). Cells
were transfected using 1 mg of plasmid per sample with Lipofectin
and PLUS reagents (Invitrogen) according to the manufacturer’s
guidelines. All experiments for this study were performed at
minimum in triplicate.
RNA Interference
siRNA gene expression knockdown studies were performed
using the TriFECTa RNAi kit (Integrated DNA Technologies)
and corresponding protocol. Each 27 mer siRNA duplex was
transfected into cells using X-tremeGene siRNA transfection
reagent (Roche) following the manufacturer’s guidelines. Trans-
fections were performed in human endothelial serum free medium
(Gibco) without antibiotics using 1 mg of siRNA per sample. All
transfections were performed 24 hours prior to experimental
conditions or analysis. siRNA was synthesized (Integrated DNA
Technologies) with the following sequences: HIF-1a:5 9- ACACG-
CAAAUAGCUGAUGGUAAGCCUC-39; HIF-1a (2): 59-AUA-
CUGUAACUGUGCUUUGAGGACUUG-39; negative control:
59- UCACAAGGGAGAGAAAGAGAGGAAGGA -39.
Flow Cytometry
Cells were stained in suspension for BrdU incorporation
8 hours after all experimental conditions with the 5-Bromo-29-
deoxy-uridine Labeling and Detection Kit I (Roche). Cells were
pre-labeled with BrdU for 30 minutes then fixed with ethanol.
Cells were then incubated with monoclonal antibodies against
BrdU mixed with nucleases, followed by fluorescein-conjugated
Figure 4. HIF-1 over-expression increases VEGF-dependent proliferation of endothelial cells. A: Immunoblotting showing increased HIF-
1a and VEGF-A165 levels in HDMEC containing the pcDNA3-HIF-1a expression plasmid. B: Flow cytometry analysis of BrdU incorporation showing
increased proliferation of cells with the pcDNA3-HIF-1a plasmid, which is prevented by VEGF neutralizing antibodies. Non-specific IgG and pcDNA3
vector were used as negative controls. C: Quantification of flow cytometry analysis of BrdU incorporation. Data represent mean (n=3)6SD; *P,0.01.
doi:10.1371/journal.pone.0042913.g004
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PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e42913Figure 5. VEGF stimulates p70S6K phosphorylation and HIF-1 expression. A: Immunoblotting showing that treatment of normal
endothelial cells (HDMEC) with exogenous VEGF-A165 increases phosphorylation of p70S6K. B: Immunoblotting showing increased expression of HIF-
1a and VEGF-A165 in HDMEC treated with recombinant VEGF-A165, suggesting an autocrine loop of signaling. Rapamycin prevents these increases. C:
Flow cytometry analysis of BrdU incorporation showing that increased proliferation of HDMEC by VEGF-A165 is inhibited in the presence of HIF-1a
siRNA. D: Quantification of flow cytometry analysis of BrdU incorporation. Data represent mean (n=3)6SD; *P,0.05.
doi:10.1371/journal.pone.0042913.g005
Figure 6. Rapamycin reduces elevated VEGF and HIF-1 levels in hemangioma endothelial cells. A: Immunoblotting showing the effects
of rapamycin on p70S6K phosphorylation, HIF-1a expression and VEGF-A165 expression in normal (HDMEC) or hemangioma (EC2, EC17B, EC21A)
endothelial cell lysates. B and C: Luminex analysis showing reduced expression of HIF-1a (B) and VEGF-A165 (C) in hemangioma endothelial cells
treated with rapamycin. Data represent mean (n=3)6SD; *P,0.05 compared to vehicle.
doi:10.1371/journal.pone.0042913.g006
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Flow cytometry was performed at the Harvard Medical School,
Department of Pathology flow cytometry core facility using a
FACSCalibur (BD Biosciences) cell sorter. Data were analyzed
using WinMDI software.
Proliferation Assays
Cells were seeded in 6-well culture dishes at 2.5610
4 cells using
human endothelial serum-free medium (Gibco). Cell counts per
cm
2 were carried out 5 days after all experimental conditions.
Immunoblotting
Cell lysates were collected using RIPA buffer (Pierce) supple-
mented with Halt protease and phosphatase inhibitor cocktail
(Pierce). Protein (20 mg) was resolved by SDS-PAGE and
transferred onto immobilon-P-membranes (Millipore Corporation)
then blocked with 5% dry milk in TBS-T (TBS (pH 7.6), 0.1%
tween20). Primary antibodies against phospho-p70S6K, p70S6K
(Cell Signaling Technology), VEGF-A165 (R&D Systems), HIF-1a
(Santa Cruz Biotechnology); b-actin (Sigma-Aldrich) were used at
a dilution of 1:1000. HRP-conjugated IgG TrueBlot secondary
antibodies (eBioscience) were used at a dilution of 1:1000. Protein
bands were visualized using an enhanced chemiluminescence
detection system (Pierce).
Immunocytochemistry
Cells grown on glass cover slips were fixed and permeablized
with cold acetone for 15 minutes then washed with PBS. Cells
were blocked with 10% FBS mixed into a solution of 1% BSA for
1 hour at room temperature. HIF-1a antibodies (Santa Cruz
Biotechnology) were used at a dilution of 1:50 in a solution of 1%
BSA for 2 hours at room temperature. Cells were then washed
Figure 7. Rapamycin inhibits proliferation of hemangioma endothelial cells. A: Flow cytometry analysis of normal (HDMEC) or
hemangioma (EC2, EC17B, EC21A) endothelial cell proliferation by BrdU incorporation in the presence of rapamycin. B: Quantification of flow
cytometry assessing the effects of rapamycin on BrdU incorporation. Data represent mean (n=3)6SD; *P,0.01 compared to vehicle.
doi:10.1371/journal.pone.0042913.g007
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secondary antibodies (Invitrogen) were used at a dilution of 1:200
in a solution of 1% BSA for 2 hours at room temperature. Cells
were washed three times with PBS for 5 minutes each then
allowed to completely dry. Vectashield (Vector Labs) fluorescent
mounting medium containing DAPI was used when attaching the
cover slips to glass slides. Images were acquired using a Nikon 80i
fluorescent microscope.
Luminex Assays
Assays were performed using the Beadlyte Universal Cell
Signaling Assay Kit and protocol (Millipore). VEGF-A165 (R&D
Systems) and HIF-1a (Santa Cruz Biotechnology), and b-actin
(Sigma-Aldrich) antibodies were conjugated to Bio-Plex carboxyl-
ated beads (BioRad) with unique optical codes using the Bio-Plex
Amine Coupling Kit (BioRad). Cell lysates were collected using
Beadlyte Cell Signaling Universal Lysis Buffer (Millipore). 25 mlo f
each lysate was added to wells of a 96-well filter plate, and mixed
with 25 ml of each 1X bead type pre-conjugated with primary
antibodies overnight shaking at 4uC. Lysates were discarded by
vacuuming the buffer through the filter at the bottom of each well,
while the beads remained in the wells. Beads were washed twice
with Beadlyte Cell Signaling Universal Assay Buffer, followed by
addition of biotinylated secondary antibodies for 1 hour at room
temperature. The biotinylated reporter was then discarded
followed by addition of streptavidin-PE for 15 minutes, then
signal amplification buffer for 15 minutes. Amplification buffer
was removed and beads were resuspended in Beadlyte Cell
Signaling Universal Assay Buffer. The beads were then analyzed
on a Luminex 200 multiplex testing system (Luminex). Beads were
detected by two lasers; one determining the bead type (each
conjugated with different antibodies) and the other determining
the amount of fluorescence given off based on the amount of
protein attached to each bead. VEGF and HIF-1 values were
divided by the b-actin control values to provide normalized data.
Statistics
One-way analysis of variance (ANOVA) was performed and
confirmed with two-tailed paired student’s t test using GraphPad
Prism4software.Pvalueslessthan0.05wereconsideredsignificant.
Figure 8. Schematic diagram of mTOR signaling in hemangioma endothelial cells. Low levels of VEGFR1 in hemangioma endothelial cells
result in constitutive VEGFR2 signaling and cell proliferation [2]. PI3K and its downstream kinase AKT are constitutively phosphorylated in
hemangioma endothelial cells as previously described [2]. Phosphorylation of p70S6K, a known target of PI3K/AKT signaling, promotes translation of
HIF-1 mRNA into protein, which translocates to the nucleus to regulate expression of target genes such as VEGF. This causes an autocrine loop of
VEGF signaling via activation of VEGFR2. The mTOR inhibitor rapamycin prevents p70S6K phosphorylation and decreases expression of HIF-1. mTOR
and HIF-1 inhibition is sufficient to reduce VEGF levels and proliferation rate of hemangioma endothelial cells.
doi:10.1371/journal.pone.0042913.g008
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Figure S1 Elevated HIF-1a in hemangioma endothelial
cells. Immunoblotting showing higher expression of HIF-1a in
hemangioma endothelial cells (EC2, EC17B, EC21A) compared to
control cells (HUVEC, HCMEC, HDMEC). b-actin was used as
an internal control.
(TIF)
Figure S2 Assessment of the effects of a second HIF-1a
siRNA duplex. A and B: Luminex analyses of HIF-1a (A) and
VEGF-A165 (B) protein levels showing that HIF-1a siRNA (2)
reduces their expression in hemangioma endothelial cells (EC2,
EC17B, EC21A). C: Proliferation assays quantifying total cell
numbers in culture 5 days after treatment showing that HIF-1a
siRNA (2) perturbs hyper-proliferation of hemangioma endothelial
cells. Data represent mean (n=3)6SD; *P,0.05 compared to
control siRNA.
(TIF)
Figure S3 Proliferation assays confirming the results of
BrdU incorporation experiments. A: Quantification of total
cell numbers in culture after 5 days of treatment with HIF-1
siRNA showing that it inhibits proliferation of hemangioma
endothelial cells. B: Total cell numbers of HDMEC 5 days after
treatment with vehicle or VEGF-A165 in the presence of control
siRNA or HIF-1a siRNA showing that VEGF-induced cell
proliferation is partially dependent upon HIF-1 expression. C:
Assessment of total cell numbers 5 days after transfection of
HDMEC with pcDNA3 or pcDNA3-HIF-1a plasmids in the
presence of non-specific IgG or VEGF-A165 neutralizing antibod-
ies (VEGF Ab) showing that HIF-1a-induced proliferation is
VEGF-dependent. D: Total cell numbers 5 days post treatment
with vehicle or rapamycin showing that rapamycin successfully
inhibits proliferation of hemangioma endothelial cells. Data
represent mean (n=3)6SD; *P,0.05.
(TIF)
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